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Maternal hypotension is a common sequala of spinal anesthesia used during cesarean 
delivery. The current first line vasopressor used for treatment of maternal hypotension is 
phenylephrine. Administration of phenylephrine can cause a physiologic decrease in 
cardiac output that could contribute to adverse maternal or fetal outcomes. This 
systematic review was conducted to investigate the use of norepinephrine as an 
alternative vasopressor for the treatment of maternal hypotension. A database search was 
conducted using electronic sources including CINAHL, MEDLINE, Google Scholar and 
PubMed. Inclusion and exclusion criteria were used to narrow search results and the 
Critical Appraisal Skills Program checklist was applied to critically appraise selected 
randomized control trials. Five articles were selected to be included in this review. Key 
outcomes were compared between studies and included incidence of maternal 
hypotension, maternal cardiac output effects, incidence of bradycardia, incidence of 
intraoperative nausea and vomiting, and fetal effects on Apgar score and umbilical cord 
gases. Overall, norepinephrine was found to be of similar effectiveness to phenylephrine 
for the treatment of maternal hypotension. When compared to phenylephrine, 
norepinephrine was found to maintain maternal heart rate better, and had a lower 
incidence of maternal bradycardia. No difference was found between intervention groups 
in fetal Apgar scores and differences in fetal cord gases were varied between studies. 
This systematic review found that norepinephrine has similar efficacy to phenylephrine in 
ability to manage maternal hypotension with lower prevalence of bradycardia. Further 
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A Systematic Review of the Prophylactic Use of Phenylephrine Versus Norepinephrine 
for The Treatment of Maternal Hypotension During Spinal Anesthesia for Cesarean 
Delivery  
Background/Statement of the Problem 
Maternal hypotension, a common side effect of spinal anesthesia during cesarean 
delivery, is a highly studied area due to its potential impact on both the mother and the 
fetus.  Rates of maternal hypotension as a consequence of spinal anesthesia performed 
during elective cesarean sections are 70-80% without prophylactic pharmacological 
management (Mercier, Augè, Hoffmann, Fisher & Le Gouez, 2013). Hypotension during 
cesarean delivery can be potentially dangerous for both mother and fetus. A common 
maternal side effect from untreated hypotension is nausea and vomiting, but side effects 
may progress to cardiovascular collapse, loss of consciousness, pulmonary aspiration and 
cardiac arrest. Maternal hypotension can also cause fetal complications such as 
uteroplacental hypoperfusion and subsequent hypoxia, acidosis and neurological injury 
(Chooi et al., 2017; Nagelhout, Elisha & Plaus, 2013). 
Currently phenylephrine is the established first-line vasopressor for the treatment 
and prevention of maternal hypotension (Nagelhout et al., 2013). Phenylephrine is a 
potent direct-acting α1-adrenergic agonist; a pure vasoconstrictor. Due to its mechanism 
of action, a reflexive decrease in heart rate (HR) and a consequent decrease in cardiac 
output (CO) are common outcomes of phenylephrine administration (Ryu, Choi, Park, & 
Kang, 2019). A 2010 study by Stewart et al. investigated the dose-dependent effects of 
phenylephrine administration during spinal anesthesia for cesarean sections and found 
marked decreases in maternal HR and CO. While the study did not show any noticeable 




on a fetus during emergent situations where fetal pH may be more acidotic. In healthy 
women, the transient decreases in HR and CO that accompany phenylephrine 
administration appears to be accommodated without detrimental effect to the fetus. 
However, there is concern that the use of phenylephrine could negatively impact 
unhealthy mothers or fetuses with compromised health. For example, mothers with 
impaired cardiac function could theoretically have greater decreases in HR and CO that 
could impact fetal wellbeing. (Carvalho & Dyer, 2015). The growing evidence that 
phenylephrine could cause detrimental effects to an at risk fetus has led to a renewed 
interest into alternative vasopressors for the use of treating maternal hypotension.  
Norepinephrine, an α1-adrenergic agonist and a mild β1-agonist, has been 
suggested as a potential alternative to phenylephrine. When used prophylactically, it has 
demonstrated the ability to maintain maternal blood pressure (BP) and increase both HR 
and cardiac contractility, while preserving CO during spinal anesthesia (Ryu, Choi, Park, 
& Kang, 2019). While investigation into the use of norepinephrine versus phenylephrine 
is relatively new and ongoing, Ngan Kee, Lee, Ng, Tan, and Khaw’s 2015 study into 
computer-controlled infusions of norepinephrine versus phenylephrine during spinal 
anesthesia for cesarean delivery found norepinephrine effective for prophylactically 
treating maternal hypotension.  
The purpose of this paper is to conduct a systematic review to investigate the use 
of norepinephrine versus phenylephrine for the treatment of maternal hypotension during 







Anesthesia during Cesarean Deliveries 
 Throughout history, there have been sporadic references to the use of cesarean 
section as a method to save both mother and infants. Purportedly the birth of Julius 
Caesar was via cesarean, and it is possible that this is the origin of the term “cesarean.” It 
is also possible the term originates from the Latin word “caedare,” which translates to 
cut, or from the term “caesones” which was historically the term applied to children born 
through postmortem procedures.  In its earliest form, the procedure was typically done on 
a dead or dying mother to retrieve an infant and the rare reports of mother and baby 
surviving are dubious. Despite medical innovations, the surgery remained a serious 
procedure limited by patient’s pain and lack of anesthesia. It was not until in the 
nineteenth century, when Queen Victoria utilized chloroform for the birth of two of her 
children that the use of anesthesia as an adjunct to childbirth became popular and 
practical (Sewell, 1993).  
 Today, cesarean deliveries are the most common major operating room procedure 
performed in the United States (HCUP Fast Stats, 2019). Modern medical advancements 
have increased the options available for anesthesia during obstetric procedures. 
Generally, there are two main types of anesthesia: general anesthesia or central neuraxial 
blocks. General anesthesia is the use of intravenous medications and/or inhaled 
anesthetics to induce a state of unconsciousness, analgesia, and amnesia (Nagelhout, et 
al., 2013). Central neuraxial blocks is the instillation of local anesthetic onto or near the 




spinal and epidural anesthesia, with spinal being typically used for non-emergent 
cesarean deliveries if an epidural has not previously been placed for labor analgesia 
(Miller & Pardo, 2011, p. 2344). Neuraxial blocks provide multiple benefits over general 
anesthesia among patients who require anesthetic management for obstetric procedures. 
Spinal and epidural anesthesia both have a lower risk for “nausea, vomiting, and urinary 
retention; a reduced total opioid requirement; and increased mental alertness compared 
with patients who have received general anesthesia alone” (Nagelhout et al., 2013, p. 
1074). Other benefits include blunting of the stress response to pain or surgical stress, a 
lower incidence of post-surgical emboli, a decrease in perioperative blood loss, and 
improvements in respiratory function and cardiac stability (Nagelhout et al., 2013). 
Ultimately the decision of neuraxial anesthesia versus general anesthesia is based on 
multiple factors, including but not limited to: fetal condition, urgency of delivery, 
maternal health and co-existing health problems, surgical concerns and maternal 
preference (Miller & Pardo, 2011,p. 2344).   
Spinal anesthesia for cesarean deliveries. 
The most common form of spinal anesthesia for cesarean delivery is a single-shot 
technique because of its reliability, ease of placement, and the quality of the sensory 
blockade achieved (Lim et al., 2018). The procedure for placing a single dose of spinal 
anesthesia is through the lumbar 3 and 4 vertebral disks. After the patient has been 
prepped and the site numbed a 22- to 25-gauge needle is advanced between the spinous 
processes. Three ligaments will be passed through before puncturing the dura and seating 
the needle within the subarachnoid space where the medication of choice will be 




of administration, the results of spinal anesthesia are the same; administration of 
medication into the subarachnoid space.    
Spinal anesthesia is commonly considered a superior option to general anesthesia 
because it is thought to be more practical and safer for mother and fetus. One way that 
fetal outcomes are assessed is through the Apgar assessment tool. It is a commonly used 
score based off five categories; heart rate, respiratory rate, newborn muscle tone, reflex 
irritability and skin coloring. Typically, the assessment is conducted at 1-minute and 
again at the 5-minute mark post-birth (Nagelhout et al., 2013).  A 2012 study by Solangi, 
Khaskheli and Siddiqui compared general and spinal anesthesia on neonatal outcomes 
found that both Apgar score and fetal pH were more affected by general anesthesia. 
Unsatisfactory Apgar scores, as defined as a score less than 7, were observed in 25% 
(n=20) of the neonates whose mothers received general versus the 2.5% (n=2) within the 
spinal anesthesia group. The study also found that fetal pH levels were increasingly 
acidotic in the general anesthesia neonatal group and concluded that spinal anesthesia is 
favorable and preferred over general anesthesia (Solangi, Khaskheli & Siddiqui, 2012).  
Maternal Hypotension. 
 Spinal anesthesia is a safe and frequently used practice; however, it is not without 
predictable, undesirable side effects. Maternal hypotension, as defined as a twenty 
percent drop in blood pressure from baseline pressure and/or a blood pressure less than 
90-100mmHg, is the most common side effect (Miller & Pardo, 2011; Nagelhout et al., 
2013). As previously mentioned, the incidence of hypotension as a side effect of spinal 
anesthesia during cesarean sections can be as high as 70-80% without prophylactic 




rates and the severity of maternal hypotension. Hypotension is primarily caused by 
hemodynamic changes due to spinal blockade and pharmacodynamic effects of local 
anesthetics, yet these hemodynamic changes can be compounded by other factors such as 
increased sensitivity to local anesthetics, the effects of pregnancy, and aortocaval 
compression of the enlarged uterus (Mercier et al., 2013). 
Spinal anesthesia uses local anesthetics to produce a sympathetic nerve block to 
mitigate pain transmission. The blockade of the sympathetic nervous system can have 
varying effects upon the cardiovascular system. These changes include: arterial 
vasodilation, a reduction in systemic vascular resistance, and a decrease in venous return 
with a resulting decrease in blood pressure (Nagelhout et al., 2013, p. 1083). Extensive 
blocks may affect the innervation of cardioaccelerator fibers, found at T1-T4, which can 
lead to a marked decrease in venous return and bradycardia. A dense T4 blockade is 
required for cesarean section, so sympathectomy of the cardioaccelerators should be 
anticipated. Resulting unopposed parasympathetic outflow can also affect the 
compensatory reflexes to decreases in blood pressure such as baroreceptors, and volume 
receptors (Miller & Pardo, 2011; Nagelhout et al., 2013).   
Pharmacological effects of local anesthetics used in neuraxial blocks may also be 
enhanced by physiologic changes because of pregnancy. As soon as the first trimester, 
pregnant women become increasingly sensitive to local anesthetic pharmacological 
affects. A study by Butterworth, Walker, and Lysak in 1990 found that median nerve 
transmission was more susceptible to lidocaine block in pregnant women versus 
nonpregnant women. It was hypothesized that changes in cellular mechanism could 




local anesthetics produce affect (Butterworth, Walker & Lysak, 1990). The increase 
sensitivity to local anesthetics may increase block height and depth of sympathetic 
blockade (Nagelhout et al, 2013, p. 1129).  
Physiological changes that occur during pregnancy can also predispose patients to 
hypotension. Pregnant women at term or near-term may be at risk for supine hypotension 
syndrome, also known as aortocaval compression, which is caused by vena cava and 
aorta compression by the gravid uterus. Aortocaval compression occurs mainly in the 
supine position when the uterus lies vertically on the aorta and vena cava which run 
concurrently along the spine. The partial occlusion of the great vessels can cause a 
decrease in venous return, decreases in stroke volume and resulting decreases in cardiac 
output (Nagelhout et al, 2013). There is an accompanying loss of arteriolar tone, which is 
why despite numerous prophylactic options to prevent hypotension, vasopressors are the 
most important treatment (Mercier et al, 2013). Physiological responses to compression 
of the vena cava and aorta are increases in heart rate and vasoconstriction of lower 
extremities, however the sympathectomy produced by spinal anesthesia may affect these 
compensatory responses which can further contribute to hypotension (Nagelhout et al, 
2013). Prevention of aortocaval compression is accomplished by left uterine 
displacement, commonly accomplished by manual displacement, or by left lateral tilt, 
either with pillow support or a 15-degree tilt of the operating room table. This 
prophylactic treatment is universally recommended to prevent a decrease in blood 
pressure and subsequent drop in venous return and collapse of cardiac output (Mercier et 





Maternal and fetal effects of hypotension. 
 Maternal hypotension, if left untreated can progress to unconsciousness, total 
cardiovascular collapse, and fetal compromise due to uteroplacental hypoperfusion 
(Nagelhout et al., 2013 p 1143). Maternal effects of unmanaged hypotension can be mild; 
nausea and vomiting, or progress to more severe side effects if left untreated. Severe side 
effects could include altered levels of consciousness, aspiration into pulmonary airways, 
decreased respiratory drive and eventual cardiac arrest (Patel, Shashank & Shivaramu, 
2018). Adequate blood pressures are critical to maintain perfusion of vital organs such as 
heart, brain, lungs, liver, kidneys and the uterus (Nagelhout et al., 2013).  
A fetal side effect of maternal hypotension is uteroplacental hypoperfusion. 
Maternal-fetal gas exchange is highly dependent on uterine and placental blood flow, 
which is maintained by maternal cardiac output (Stewart et al., 2010). In normal adult 
circulation, waste products of aerobic metabolism such as carbon dioxide are exhaled and 
exchanged for oxygen, thus regulating the acid-base balance within the body. The fetus is 
unable to exhale and is thus dependent on maternal circulation for the delivery of oxygen, 
and after fetal metabolism the excretion of waste products (Fahey & King, 2010). Uterine 
and placental hypoperfusion impacts fetal gas exchange which can create a state of 
anaerobic metabolism within the fetus. Without oxygen exchange, hydrogen ions form 
organic acids such as lactic acid which negatively impacts the fetal acid-base balance 
(Nagelhout et al., 2013; Fahey & King, 2010). Normally adult pH is within the range of 
7.35-7.45 while normal umbilical artery pH of newborns is 7.25-7.30 indicating fetal 
homeostasis is maintained at a slightly more acidotic pH (Thorp, Sampson, Parisi & 




The natural progression of labor can produce transient periods of uteroplacental 
hypoperfusion as the uterus contracts and interrupts normal blood circulation through the 
placental barrier. Adaptive mechanisms for the fetus will maintain normal hemostasis 
during these events, however when low perfusion states are prolonged such as during 
maternal hypotension it can lead to fetal hypoxia. An increase in hydrogen ions from lack 
of oxygen exchange will cause a decrease in fetal pH and respiratory acidosis. 
Subsequently if hypoxemia and hypoxia continue, anaerobic metabolism will begin 
producing lactic acid causing metabolic acidosis (Fahey & King, 2010). Post-partum 
neonatal umbilical cord blood pH is routinely tested and is used as a predictor of fetal 
outcomes. A 2019 study by Rimsza, Perez, Babbar, O’brien and Vricella investigated the 
correlation between time of neuraxial placement to neonatal delivery and the effects of 
umbilical arterial cord pH and found that maternal hypotension was one of the predictive 
factors of decreasing neonatal pH levels. Cases with extended start times had lower 
umbilical arterial pH along with lower venous pH and elevated pCO2 levels which is 
consistent with fetal respiratory acidemia (Rimsza et al., 2019). Cases may have delayed 
start times for numerous reasons, including but not limited to surgeon delay, operating 
room availability, supply constraints, staffing issues or complications related to prepping 
the patient for a procedure.  
Interventions for Prevention and Treatment of Hypotension  
 Providers use a range of techniques to prevent and treat hypotension; intravenous 
fluid administration, physical interventions such as uterine displacement or compression 
devices, and pharmacological treatments (Choi et al., 2017). For several decades, fluid 




George & Habib, 2017). Numerous studies have examined fluid therapy, studying the 
type of fluids; crystalloid fluid versus colloid fluid, timing of the administration; 
preloading versus co-loading in regard to timing of the block, and optimal quantities of 
fluid to be administered. Although fluid administration will increase intravascular space, 
thereby increasing cardiac output, it is thought that the fluid rapidly redistributes, and 
rates of hypotension continue to be high (Lee, George & Habib, 2017). Currently, there is 
no study that definitively shows that an ideal fluid type or amount will negate maternal 
hypotension on its own. 
 As previously discussed, patient positioning can improve blood flow and is an 
important nonpharmacological intervention for preventing hypotension. While uterine 
displacement is widely accepted as a nonpharmaceutical intervention, manual 
displacement of the uterus by the provider appears to have superior efficacy when 
compared to left lateral tilt of the patients hips or operating room table (Choi et al., 2017). 
Other techniques such as lower leg compression or elevation of the legs do not appear to 
be overtly effective, however few studies have examined these techniques and those that 
did had small cohorts (Choi et al., 2017).   
 Vasopressors have been found to be the most important intervention in the 
treatment of maternal hypotension (Mercier et al., 2013). Ephedrine, a synthetic indirect-
acting sympathomimetic that has both alpha- and beta-adrenergic receptors, was 
historically the vasopressor of choice (Nagelhout et al, 2013). A shift away from 
ephedrine occurred after increasing evidence showed that ephedrine crosses the placenta 
barrier with an associated decrease in umbilical arterial pH and base excess (Ngan Kee, 




vasopressor for treatment and prevention of maternal hypotension (Nagelhout et al., 
2013). Recently, evidence has shown that phenylephrine has the propensity to decrease 
maternal heart rate and cardiac output which could potentially have deleterious effects to 
the fetus (Stewart et al., 2010). As a result, there has been a renewed interest in 
alternative vasopressors such as norepinephrine to treat maternal hypotension.  
Phenylephrine  
 Phenylephrine (Neo-synephrine) is a direct-acting sympathomimetic amine that 
has α1-adrenergic agonist with minimal to no beta-adrenergic affinity. It has FDA-
approval for the use of treatment for clinically significant hypotension from vasodilation, 
such as from neuraxial anesthesia (Richards & Maani, 2019).  It is an ideal vasopressor 
because it has a quick onset, short duration, and has expected dose-dependent responses. 
Intravenous (IV) phenylephrine has potent vasoconstriction properties which can increase 
preload, systemic vascular resistance and afterload. However, phenylephrine’s 
stimulation of alpha-adrenergic receptors only can lead to baroreceptor-mediated reflex 
bradycardia (Richards & Maani, 2019). This decrease in heart rate and consequent 
decrease in cardiac output raises concern over uteroplacental perfusion side effects 
(Carvalho & Dyer, 2015).  
Norepinephrine  
 Norepinephrine is a sympathomimetic amine which primarily works as an α1-
adrenergic agonist with β1-agonist with mild to no effect on β2 or α2 receptors. 
Structurally it is identical to epinephrine, but a lack of methyl group on its nitrogen atom 
affects its site of action. It is FDA-approved for blood pressure control during acute 




septic shock (Smith & Maani, 2019). Norepinephrine has strong vasoconstricting 
properties with less potent direct inotropic abilities and minimal chronotropic effects 
which is beneficial for patients whose heart rate stimulation is unwarranted (Overgaard & 
Džavik, 2008). Norepinephrine primarily increases both systolic and diastolic blood 
pressures, with an increase to pulse pressure and a minimal net impact on patients’ 
cardiac outputs (Overgaard & Džavik, 2008).  
 Due to norepinephrine’s strong vasoconstricting properties, concern exists for 
potentially severe complications if administered through a peripheral venous catheter. 
Complications include extravasation, thrombophlebitis, localized cellulites, and tissue 
necrosis (Nagelhout et al., 2013). A recent observational study investigated the 
complications from vasopressor administration via peripheral venous catheters. 
Significant morbidity was not established, and the authors found that administration of 
norepinephrine through peripheral IVs for a median duration of 13 hours [interquartile 
range of 6.5-31.5 hours] had a low rate (5.5%) of minor complications which did not 
require any intervention (Medlej et al., 2017).  It is still recommended that instillation of 
norepinephrine should be through a large-bore peripheral catheter, ideally in the 
antecubital vein or through a central venous catheter.  
 The use of norepinephrine as an alternative to phenylephrine for the treatment of 
maternal hypotension is a relatively novel idea. In the United States norepinephrine’s 
area of use is typically the intensive care unit or in cardiac anesthesia while 
phenylephrine is a commonly used medication readily available in the operating room. 
The possible future use of norepinephrine could be met with logistical and culture 




norepinephrine as a potential alternative to phenylephrine due to its lower incidence of 
bradycardia and minimal decreases in cardiac output.  


























The PRISMA framework was used as the theoretical framework for this 
systematic review. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRIMSA) Statement was developed from the QUOROM Statement (Quality of 
Reporting of Meta-Analyses) which was developed in 1996 (Moher, Liberarti, Tetzlaff, 
Altman, & The PRISMA group, 2009). The updated and revised PRISMA Statement 
addresses multiple advances that have been made in the science among systematic 
reviews (Moher et al., 2009). The goal of PRISMA is to aid investigators in their 
assessment of systematic reviews and aid in the writing of a systematic review using a 
flow diagram and checklist.  The use of PRISMA ensures increased transparency among 
systematic reviews and aims to minimize potential bias from study selection.  
The PRISMA Statement includes a 27-item checklist (Appendix A) and includes 
seven major categories: title, abstract, introduction, methods, results, discussion, and 
funding. Subheadings within the major categories go on to describe the checklist item in 
further detail.  In addition to the checklist, The PRISMA Statement also consists of a 
four-phase flow diagram (Figure 1), illustrated on the next page. The flow diagram helps 
guide the identification, screening, eligibility and inclusion or exclusion of research 
studies (Moher et al., 2009). The comparative use of norephedrine versus phenylephrine 
to prevent or in treatment of maternal hypotension is a recent idea with limited research. 
The current, available randomized controlled trials were assessed utilizing the PRIMSA 















The purpose of this paper was to conduct a systematic review to investigate the 
use of norepinephrine versus phenylephrine for the treatment of maternal hypotension 
during spinal anesthesia for cesarean delivery.  
Inclusion and Exclusion Criteria 
Inclusion criteria was randomized control trials that investigated the use of 
phenylephrine and/or norepinephrine for the treatment of maternal hypotension during 
spinal anesthesia for cesarean delivery. Studies published between January 2009 to 
December 2019 that include women 18-55 years of age undergoing scheduled or 
emergent cesarean delivery were included. Women with past medical histories of pre-
eclampsia were also included. Outcomes included were maternal hemodynamics; HR, 
CO, BP, and fetal outcomes; Apgar score, pH and umbilical blood gases. Exclusion 
criteria was studies published before 2009 and those not in the English language, and 
studies involving non-cesarean delivery use of phenylephrine or norepinephrine.  
Search Strategy 
  The search was conducted using the databases CINAHL, MEDLINE, Google 
Scholar and PubMed. The terms searched were Phenylephrine, Norepinephrine, spinal 
anesthesia, maternal hypotension, low blood pressure, cesarean delivery and/or c-section, 
complications, fetal compromise and randomized control trial. The planned search was 
limited to the above-mentioned inclusion criteria. The PRISMA flowchart and checklist 
were used to evaluate and validate selected randomized control trials.  




Data Collection  
 Data collected through the above methods was organized in a data collection 
table, depicted below (Table 1). The study characteristics included in each table were the 
studies purpose, sample/setting, anesthesia provided, interventions, outcomes and any 
limitations within the study. Tables were completed for each randomized control trial 
selected for this study and analyzed for relevant data (Appendix C).  
Table 1 




Anesthesia Intervention Outcomes Limitations 
     
 
Critical Appraisal  
The Critical Appraisal Skills Program (CASP) checklist was utilized to critically 
appraise the randomized control trials selected for this systematic review. The 11-item 
CASP checklist was utilized in evaluating the results of each randomized control trial and 
identifying any limitations or biases within the studies. CASP considers three issues 
when considering and appraising a trail: Are the results valid, what are the results, and 
will the results help locally? The first three questions are progressive and if the answer is 
“yes” it is suggested to proceed to the remaining questions. Most of the remaining 
questions may be answered with a “yes,” “no,” or “can’t tell (CASP, 2018).” The CASP 
checklist was completed for each randomized control trial selected for this systematic 





Figure 2. CASP Checklist (CASP, 2018) 
 
Data Synthesis  
 A data synthesis table was created to synthesize data extracted from the five 
selected randomized control trails. A cross study analysis was performed to identify 
effects of norepinephrine versus phenylephrine for the treatment of maternal hypotension 
during spinal anesthesia for cesarean delivery. The data was organized into a table with 
the focus on effects on maternal hypotension, incidence of bradycardia, effects on cardiac 
output, incidence of nausea and vomiting, neonatal Apgar scores and effects on umbilical 
cord gases. The data synthesis table (Table 2) was used for cross-study analysis and 





Data Synthesis Table 
 










































        





A database search was conducted and a total of 15 non-duplicate citations were 
screened. The completed PRISMA diagram shows the elimination of citations (Figure 3). 
The titles and abstracts were reviewed for inclusion or exclusion criteria and 7 articles 
were excluded based off preliminary analysis. One article was excluded after data 
extraction. The five remaining articles were reviewed completely, and inclusion and 
exclusion criteria were again applied with no articles needing to be eliminated. The five 
articles were included in this systematic review.  
 
Figure 3. Completed PRISMA flow diagram demonstrating article screening, inclusion or 




Individual Study Analysis 
In 2015, Ngan Kee et al. published the landmark RESPOND study, a randomized 
control study evaluating the use of phenylephrine verses norepinephrine for the 
maintenance of blood pressure after spinal anesthesia for cesarean delivery (Appendix B-
1). The study compared the use of computer-controlled closed loop infusions of the study 
drugs for the maintenance of maternal blood pressure. The primary outcomes assessed 
were maternal heart rate (HR) and cardiac output (CO). Secondary outcomes were 
neonatal outcomes and assessment of umbilical cord gases.  
Sample size was calculated based on the authors previously published and 
unpublished studies which evaluated hemodynamic data from obstetric patients. A 
sample size of 47 patients per group was calculated to have a larger than 90% power to 
detect a 20% change in CO between study groups five minutes after intrathecal injection 
with an α error probability of 0.05. Polynomial data was analyzed using the Kolmogorov-
Smirnov test and cross analyzed using Student t test or the Mann-Whitney U test. 
Nominal data was assessed using the chi-square test of the Fisher exact test. Values for 
CO, stroke volume (SV), and systemic vascular resistance (SVR) were measured 
noninvasively using suprasternal Doppler and values were normalized to percentage of 
baseline. Due to the variable times to complete measurements for HR and systolic blood 
pressure (SBP) data was grouped according to chronological recording. 
Initially 104 women were recruited into the Ngan Kee et al., (2015) study. 
Exclusion data was applied and 49 patients were randomized into the norepinephrine 




received standardized treatments upon study admittance and patient characteristics and 
surgical times were comparable between groups. All patients were fasted the night prior 
to the c-section and received prophylactic antacid medications. On arrival to the 
operating room baseline hemodynamics were recorded with pulse oximetry, 
electrocardiography, and non-invasive blood pressure with mean arterial blood pressures 
(MAP) being calculated from the latter. CO, SV, and SVR were also obtained and 
repeated three times for baseline value. All hemodynamics were measured by an 
experienced operator who was blinded to patient group assignment.  
After a large-bore intravenous cannula was placed all patients received 
standardized spinal anesthesia in the right lateral position. Infusion of study drugs was 
started at the time of intrathecal injection. A solution of either norepinephrine 5mcg/ml or 
phenylephrine 100 mcg/ml was administered from prepared 50-mL syringes that were 
labeled “study drug.” The concentration of norepinephrine 5mcg/mL or phenylephrine 
100 mcg/mL were thought to be equipotent at a ratio of 20:1 based on previous 
comparative studies done by Sjöberg, Andersson, and Steen (1989). The study drug 
administration was regulated using a computer-controlled closed-loop feedback system 
based off the patients SBP which was set to cycle every 1 minute. The infusions were 
initially started at 30mL/hour and after completion of the first SBP measurement the rate 
was adjusted based off the computer algorithm. Administration rates were limited to 0-60 
mL/hour (range of 0-5 mcg/minute of norepinephrine and 0-100 mcg/minute of 
phenylephrine) and defaulted to a rate of 0 mL/hour if the patients HR was <50 beats per 




Serial hemodynamics were monitored throughout the cesarean delivery; BP and 
HR were set for 1-minute cycle times, while CO, SV, and SVR were measured in 5-
minute intervals. Of note, one patient from group N required supplemental oxygen for a 
pulse oximeter reading <95%. After delivery, the neonate’s Apgar score was assessed by 
a midwife at the 1-minute and 5-minute post-delivery mark. Samples of umbilical arterial 
(UA) and umbilical venous (UV) blood were collected from a double-clamped stretch of 
the umbilical cord. Samples with insufficient blood quantity or equipment failure were 
accounted for within the study.  
The study outcome concluded that maternal SBP was maintained similarly 
between study groups, but norepinephrine use correlated with a greater HR and CO with 
a lower SVR.  It found that CO at the five-minute point was higher in group N versus 
group P, with a P value of 0.004. SVR was lower in the group N when compared to group 
P (P<0.001). Group N rates of bradycardia (defined as a HR <60 bpm) were less then 
group P (18.4% vs 55.8%, P<0.001). There was no difference in SV between groups 
(P=0.44). Ngan Kee et al., attributed the greater CO in group N to be primarily related to 
the lower incidence of bradycardia since CO is based off a patients HR and SV. UV pH 
and UV oxygen content were higher in group N which the authors attributed to the 
greater placental blood flow theoretically from the increase in CO. Neonatal outcomes 
were found to be otherwise similar between groups. The authors concluded that 
norepinephrine and phenylephrine have similar efficacy for the maintenance of blood 
pressure following spinal anesthesia for cesarean delivery, but norepinephrine maintained 




to investigate norepinephrine and its safety for use among obstetric patients, modes of 
administration, and relative potency of norepinephrine versus phenylephrine.  
The 2019 study by Wang, Mao, Liu, Xu & Yang, compared the efficacy and 
safety of bolus dose norepinephrine, phenylephrine and ephedrine for the treatment of 
hypotension during cesarean delivery under spinal anesthesia for parturients with 
preeclampsia (Appendix B-2). The primary outcome measured was maternal SBP and 
HR. Secondary outcomes assessed were incidence of tachycardia, bradycardia, and 
hypertension. The amount of vasopressor required, number of hypotensive episodes, 
maternal side effects and neonatal outcomes were also analyzed.  
Wang et al., enrolled parturients between January and June of 2018 at a hospital 
in Nanjing, China. Sample size was calculated based off a pilot study that examined the 
rates of tachycardia with the use of norepinephrine or ephedrine treating parturients with 
preeclampsia. A minimum of 49 cases per group was calculated to detect a statistically 
significant difference in rates of tachycardia between groups. The sample size was 
increased to 55 patients per group to account for possible drop out. Univariate data was 
analyzed using D’Agostino-Pearson omnibus normality test and one-way analysis of 
variance (ANOVA) and then by a two-sample t-test or Mann-Whitney test. Nominal data 
was analyzed using a chi-squared test or Fisher’s exact test. A p-value of <0.05 was 
considered to be statistically significant. 
A total of 368 women were initially recruited into the study. After inclusion and 
exclusion criteria was applied 315 patients were randomized into the three study groups. 




were included in the final analysis.  Final enrolled participants included 56 patients 
allocated to the norepinephrine group (group N), 55 patients to the phenylephrine (group 
P) and 55 patients to the ephedrine (group E) group. Inclusion criteria was American 
Society of Anesthesiologist (ASA) status I-II, singleton pregnancy scheduled for spinal 
anesthesia and included a diagnosis of pre-eclampsia. Pre-eclampsia was defined as at 
least two BP readings of ≥140/90 mmHg in a four-hour interval, with a 24-hour 
proteinuria of ≥300 mg or ≥1+ with a dipstick. Parturients with severe pre-eclampsia 
were also included in the study. Severe pre-eclampsia was defined as a BP reading of 
≥160/110 with any of the following comorbidities; low platelets, cerebral or visual 
disturbances, pulmonary edema, altered liver function and impairment of renal function.  
Patients received standardized treatment regarding anesthesia and study 
medication administration. Upon entering the operating room, participants were 
positioned in supine, left uterine displacement position and three consecutive readings of 
BP, HR, and pulse oximetry were taken for baseline value. An independent researcher 
recorded all maternal hemodynamic values; BP and HR were recorded every minute from 
intrathecal anesthesia instillation until neonatal delivery. Patients were positioned in the 
left lateral position and received an intrathecal injection of 2.0-2.2 ml of hyperbaric 
bupivacaine 0.5%. Immediately following injection, patients were returned to the left 
uterine displacement supine position and received Ringer’s lactate hydration at a 
maximum rate of 10ml/kg. Hypotension following intrathecal injection was defined as an 
SBP <80% of patients baseline readings and treatment was administration of the selected 
study drug. Based off group assignment, patients received either norepinephrine 4mcg, 




bradycardia, defined as a HR of <60 bpm. The study endpoint was delivery of the 
neonate. After delivery umbilical artery blood was collected from a double-clamped cord 
and a pediatrician evaluated the neonate using the Apgar scoring system at one minute 
and five minutes. Blood gases that could not be accounted for due to insufficient blood 
samples or equipment failure were accounted for within the groups.  
Due to the diagnosis of pre-eclampsia, multiple patients within the study groups 
were receiving antihypertensive treatments (group N n=42, group P n=40, group E n=40). 
Ten women in group N, twelve women in group P, and eight women in group E were 
diagnosed with severe pre-eclampsia. Within those diagnosed with severe pre-eclampsia, 
six in group N, five in group N, and five in group E received magnesium sulfate as a 
prophylaxis against seizures, a risk of severe pre-eclampsia. Of note, not included in the 
study was the type of antihypertensive patients were prescribed or if those medications 
could have affected study medications administered.  
The outcome of Wang et al., 2019 study into the efficacy and safety of bolus 
norepinephrine, phenylephrine, and ephedrine concluded that overall all three 
medications were effective in the treatment of spinal hypotension in pre-eclamptic 
women (Appendix D). However, group N was found to be superior to other study 
medications at maintaining HR. Group N had less incidence of tachycardia (defined as a 
HR >120 bpm) when compared to group E (16.1% vs 36.4%; P=<0.05) and less 
incidence of bradycardia when compared to group P (3.6% vs 21.8%; P=<0.004). No 
statistical difference was found between groups in the number of hypotensive episodes, 
the number of boluses required, or the incidence of hypertensive episodes. Incidence of 




versus group E (20%) (P=0.02). Neonatal Apgar scores were similar among groups and 
no neonate had an Apgar score of <9 at the five-minute assessment. Fetal UA pH was 
higher in group N versus group E (7.32 ±0.02 vs 7.31 ±0.031; P=0.006). Among the 
groups, no neonate had fetal acidosis, defined as an UA pH <7.20. UA lactate was also 
found to be lower in group N (1.3±0.3) verses group E (1.8±0.5) (P=<0.001). No 
statistically significant differences were found in the UA blood gases between groups N 
and P. The authors concluded that while norepinephrine had similar efficacy for the 
maintenance of SBP when compared to the other study drugs, it had an improved 
maternal safety profile when compared to phenylephrine. They also stated that 
norepinephrine had an improved maternal and neonatal safety profile when compared 
with ephedrine.  
The 2017 study by Vallejo et al., compared the use of prophylactic infusions of 
phenylephrine versus norepinephrine for the maintenance of systolic blood pressure 
during cesarean delivery under spinal anesthesia (Appendix B-3). The primary outcome 
measured was the number and total dose of rescue boluses needed to maintain SBP in 
addition to the study drug infusion. Secondary outcomes measured were maternal 
hemodynamics; HR, CO, cardiac index (CI), SV, and SVR. Fetal outcomes such as 
Apgar score at 1 minute and 5 minute and umbilical cord blood gases were also analyzed 
of obtained as part of the neonate’s routine care.  
The Vallejo et al., study enrolled 85 patients into their study between August 
2014 and August 2015. The authors calculated sample size based off a local pilot study 
which indicated that 35 parturients were required per group to detect a decrease to 10% in 




study size was increased to 85 patients to account for dropout. A two-sample Z-test was 
utilized to analyze the difference between groups in the number of patients requiring at 
least one rescue bolus. Nominal data for secondary outcomes was analyzed using the chi-
squared test. Hemodynamic parameters and trends were analyzed using multivariate 
analysis of variance (MANOVA).  A P value of <0.05 was considered to be significant.  
Patients were randomized to two treatment groups using a computer-generated 
table. Group one (group P, n=38) received a fixed rate infusion of 0.1mcg/kg/min 
phenylephrine while group two (group N, n=39) received 0.05 mcg/kg/min 
norepinephrine also at a fixed rate. Inclusion criteria included an ASA status of <III, >36-
week singleton pregnancy with a BMI <40kg/m2. Patient characteristics and 
demographics were similar between both study groups. All patients were accounted for at 
the conclusion of the study and once enrolled patients received standardized treatment.  
All patients had preoperative SBP and HR measured three times consecutively 
and averaged for a baseline. Prior to entering the operating room study participants 
received 500mL of lactated Ringers solution intravenously. Upon entering the operating 
room, patients received a standardized spinal anesthetic in the sitting position consisting 
of hyperbaric bupivacaine 12-15mg with an opioid adjunct of fentanyl 20mcg and 
preservative-free morphine 0.2mg intrathecally. The selected study drug, which was 
made aware to the anesthesia provider upon patient arrival, was started at the time of 
intrathecal injection. Hypotension was defined as a decrease below 100% of baseline and 
was treated with a rescue bolus of 100 mcg phenylephrine. Bradycardia as defined as a 
HR <60 bpm was treated by infusion discontinuation and if compounded with 




for any episodes of hypertension, as defined by an SBP >120% of baseline. 
Hemodynamics were continuously recorded using a non-invasive hemodynamic monitor. 
The study endpoint was at the point of transfer of care back to labor and delivery 
postoperatively.  
The study by Vallejo et al., concluded that prophylactic fixed-rate infusions of 
norepinephrine were efficacious for the prevention of hypotension after spinal anesthesia 
during cesarean delivery. The study found no difference between groups in study drug 
infusion length, incidence of bradycardia, or non-invasive hemodynamic parameters (HR 
P=0.17, CO P=0.5, SVR P=0.54). The number of patients who received ≥1 rescue bolus 
of phenylephrine was similar between groups (Group P 52.6% vs group N 46.5%, 
P=0.58). However, the use of ≥1 bolus of rescue dose ephedrine was higher in group P 
(23.7%) in comparison to group N (2.3%) (P<0.01). Overall incidence of IONV was 
similar between groups however the incidence of emesis was greater in group P (26.3%) 
than in group N (1.63%) (P<0.001). No statistically significant difference was found in 
fetal Apgar scores <7 at 1 minute (P=0.82) or 5 minutes (P=0.48) and UV pH were 
similar between groups (P=0.42). The authors concluded that norepinephrine infusions 
can be considered as an alternative to phenylephrine however future research is required 
to analyze its overall safety.  
The 2018 randomized control trial by Sharkey et al., investigated the use of bolus 
dose phenylephrine verses norepinephrine to prevent and treat hypotension during 
cesarean delivery (Appendix B-4).  The primary outcome assessed was rate of maternal 
bradycardia as defined as a HR <50 bpm. Secondary outcomes assessed included the 




episodes of nausea and/or vomiting. Fetal outcomes were also assessed through umbilical 
gas analysis, and fetal Apgar scores.  
Study sample size was calculated based on two previously conducted studies by 
Sharkley et al., research group. A sample size of 112 total participants was estimated to 
achieve 80% power to detect a 70% decrease in the episodes of bradycardia in each group 
with a significance level of 0.05. The goal of 56 participants per group accounted for an 
anticipated 5% withdrawal rate. Data for the primary outcome, bradycardia, was analyzed 
using the  2 test. Secondary outcomes were compared using the  2 test or the Fisher 
exact test for categorical variables, and the Student t test or Wilcoxon rank sum test, 
when appropriate for continuous variables. A P value of <0.05 was considered to be 
statistically significant.  
Between January 3, 2017 and April 17, 2017 Sharkey et al., enrolled 112 eligible 
parturients to be placed evenly into two treatment groups. Patients were randomized into 
their respective treatment groups using computer generated block randomizations. Group 
one, (group P, n=56) received a standard dose of phenylephrine 100mcg while group two 
(group N, n=56) received a standard dose of norepinephrine 6mcg. The study drugs were 
administered manually by an anesthesia provider, who was blinded to group allocation, to 
prophylactically prevent or treat hypotension as defined as an SBP <80% baseline value.   
Inclusion criteria for study participants included an ASA status of ≤III, singleton term 
pregnancy with a weight between 50-100kg. Patients received standardized treatments 
upon study admittance and patient characteristics were similar between the two treatment 
groups. All patients had preoperative SBP and HR measured three times one minute apart 




standard monitoring equipment and positioned in the sitting position. Standardized spinal 
anesthesia was administered in the L3/4 interspace as identified by ultrasound. 
Immediately after intrathecal injection patients were coloaded with 10mL/kg (maximum 
of 1 liter) of lactated Ringer’s infusion via pressure bag infusion. Patients were positioned 
left lateral tilt and SBP, HR and pulse oximetry were monitored every 1 minute for the 
duration of the study which  continued from the time of intrathecal injection to the 
delivery of the fetus. Selected study drugs could be administered as often as one minute 
prophylactically or for any episode of hypotension. Rescue boluses of ephedrine 10mg 
were administered for any hypotensive episodes coinciding with a HR <60 or for any 
hypotensive episodes lasting more than 2 consecutive BP readings regardless of study 
drug administration.  
The study outcome by Sharkey et al., concluded that intermittent bolus doses of 
norepinephrine to prevent hypotension during cesarean delivery had a lower incidence of 
bradycardia when compared to bolus dose phenylephrine (Appendix D). The rate of 
bradycardia was lower in group N when compared to Group P (10.9% vs. 37.5%; 
P=<0.001) which implied a relative reduction of 71%. Using the  2 test to analyze the 
data, it was found that patients in group P had a higher risk of having multiple episodes of 
bradycardia when compared to group N (P=0.008). While there was no statistical 
difference between groups regarding rates of hypotension (P=0.9), the incidence of 
patients requiring rescue boluses of ephedrine for 2 consecutive hypotensive SBP 
readings was higher among group P (21.4%) verses group N (7.2%) (P<0.3). Rates of 
nausea and vomiting were similar between groups (P=0.57, P=0.17 respectively). Fetal 




minute assessments for either group. There was no statistical difference in umbilical 
arterial or venous blood gases between the two groups. The authors concluded that 
phenylephrine and norepinephrine had similar efficacy for the maintenance of maternal 
blood pressure during spinal anesthesia for cesarean delivery, however norepinephrine 
had a lower incidence of bradycardia.  
The 2019 randomized control trial by Mohta, Garg, Chilkoi and Malhotra 
investigated the use of phenylephrine verses norepinephrine for the treatment of 
hypotension following spinal anesthesia for caesarean section (Appendix B-5). The 
primary outcome measured was rates of maternal bradycardia following study drug 
administration. Secondary outcomes were overall blood pressure changes, study drug 
requirements, maternal complications, and neonatal outcomes.  
Mohta et al., recruited 90 parturients between December 2016 to January 2018. 
All patients who entered the trial were properly accounted for throughout the study. 
Inclusion criteria was a singleton, uncomplicated, term pregnancy. Participants were 
randomized into group allotments via a computer-generated random number table and 
investigators, anesthesia providers and patients were blinded to group allotment. Study 
recruitment size was based off a previously done study by Mohta et al., which found that 
a sample size of 45 patients per group would show a clinically significant 60% decrease 
in incidence of bradycardia with norepinephrine with a power of 80% at a 0.05 
significance level. Primary study data was analyzed with the Fisher’s exact test. 
Hemodynamic and other parameters were tested by the Shapiro-Wilk test as appropriate. 
Normally distributed variables were analyzed using the unpaired students t-test. Non-




scores were analyzed with the Mann Whitney U-test and a p value of <0.05 was 
considered to be significant. SBP and HR were compared with a linear mixed model and 
a p value of <0.01 was considered significant.  
Women enrolled were randomized into two study groups for the Mohta et al., 
2019 study. Group one (group P, n=45) received a bolus of 100 mcg of phenylephrine IV 
for any hypotensive SBP episode, while group two (group N, n=45) received a 5 mcg 
bolus of norepinephrine. Hypotension was defined as a decrease of ≥20% from SBP 
baseline or an SBP <100 mmHg. Baseline SBP and HR were obtained upon entering the 
operating room and based off an average of three consecutive recordings. All participant 
received Ringer’s lactate solution at a rate of 15 ml/kg via IV which was initiated upon 
entering the operating room. Standard spinal anesthesia was performed in the sitting 
position and after administration patients were positioned left uterine tilt supine position. 
All patients received 40% oxygen via facemask until fetal delivery. Patients HR and BP 
were monitored every minute starting after spinal administration and study end point was 
set at delivery. Patients received the selected study drug for any episode of hypotension 
as previously defined. Bradycardia was defined as a HR of <60 bpm and 0.6 mg IV of 
atropine could be administered for any episode of bradycardia combined with 
hypotension or for an absolute HR <45 bpm. Neonatal Apgar scores were assessed at 1 
minute and 5 minutes post-delivery. UA and UV blood gases were sampled prior to the 
baby’s first breath via a double clamped segment of umbilical cord.  
Finally, Mohta et al., concluded that there was no significant difference in the 
rates of maternal bradycardia when using phenylephrine or norepinephrine for the 




comparable between the group P (37.8%) and group N (22.2%) (P=0.167). There was no 
statistically significant difference between groups in the incidence of hypotensive 
episodes (P=0.06). However, the total number of vasopressor boluses required to treat 
hypotensive episodes was higher in group P than group N (P=0.01). Rates of maternal 
nausea, vomiting and dizziness were comparable between the two groups (P=1.00). 
Umbilical blood gases showed higher levels of UA pH in group P (mean 7.29) versus 
group N (7.25) (P=0.03). Fetal levels of bicarbonate and base excess in UA and UV 
samples were also higher among group P than group N. No significant difference was 
found between groups regarding Apgar scores at 1 minute or 5 minutes. The study 
concluded that 100 mcg of phenylephrine and 5 mcg of norepinephrine were similar in 
their ability to treat hypotension after spinal anesthesia and had no significant difference 
in incidence of bradycardia. Due to the differences found in umbilical blood gases, the 
authors concluded that more research is warranted into placental transfer and metabolic 
effects of norepinephrine.  
Cross Study Analysis  
 The data synthesis table (Appendix D) demonstrates the key outcomes across the 
five studies. All five studies were current, randomized control trials that directly 
compared phenylephrine to norepinephrine, apart from Wang et al., which also compared 
ephedrine. The method of medication administration varied between studies and included 
closed loop computer administration, bolus dose administration, or fixed rate infusions. 
All of the studies investigated the incidence of maternal hypotension and incidence of 
bradycardia. Maternal cardiac output effects were investigated in two of the five studies; 




 Patient characteristics and treatment were comparative throughout the studies 
except for Wang et al., 2019 which enrolled women with a diagnosis of preeclampsia. All 
patients included were ASA I-III, singleton, >36-week pregnancies who received spinal 
anesthesia for scheduled cesarean delivery. Selected spinal anesthesia was single-dose 
hyperbaric bupivacaine administered into the lumber space. There were variations among 
the studies regarding the use of narcotics; morphine and/or fentanyl included in the 
intrathecal anesthesia. Parturients were hydrated with either Hartmann’s solution or 
Ringer’s Lactate with dosing ranging from 10ml/kg to 2L cumulative.  
 Among the five studies, hemodynamics were monitored throughout the surgical 
period using a variaty of noninvasive monitors. The definitions of hypotension varied 
between trials. Hypotension was defined as an SBP <80% of baseline in the majority of 
studies with the exception of  Vallejo et al., 2017 which defined it as a decrease of 
<100% of baseline, and Mohta et al., 2019 defined it as a decrease of  ≥20% or an 
absolute value of <100 mmHg. None of the studies found a statistical difference between 
the rates of hypotensive episodes between the norepinephrine or phenylephrine treatment 
groups. Cardiac output was monitored in Ngan Kee et al., 2015, and Vallejo et al., 2017. 
Data was conflicting between the two studies, with Ngan Kee et al., finding that 
normalized CO at 5 minutes after spinal anesthesia to be greater within the 
norepinephrine treatment group and Vallejo et al., 2017 finding no difference between 
treatment groups.  The definition of bradycardia was defined as a heart rate of <60 beats 
per minute in all the studies except Sharkey et al., 2018 which defined it as a heart rate of 
<50 beats per minute. Three of the five studies found the incidence of bradycardia to be 




 Maternal incidence of intraoperative nausea and vomiting (N/V) between 
treatment groups was analyzed among the five trials. Four of the five studies found no 
statistical difference in rates of N/V between study groups. Vallejo et al., 2017 reported 
incidence of nausea and vomiting separately and found that while rates of nausea were 
similar between groups, the incidence of emesis was higher in the phenylephrine 
intervention group.  
 Fetal Apgar scores at 1 minute and 5 minutes post delivery were collected in all 
five trials. All five studies found that Apgar scores were similar between groups at both 
assessments. Fetal umbilical cord gases were collected in all five trials. After applying 
the data synthesis table no themes could be obtained between the studies regarding cord 
gas analysis. Ngan Kee et al., 2015 found that UV pH was greater in the norepinephrine 
treatment group (mean: 7.35), while Mohta et al., 2019 showed that UA pH was higher in 
the phenylephrine treatment group (mean: 7.29).  UV oxygen content was found to be 
higher in only one study; Ngan Kee et al., in the norepinephrine intervention group.  
 Results from the five RCTs included in this systematic review demonstrated that 
phenylephrine and norepinephrine had similar efficacy in the maintenance of maternal 
blood pressure following spinal anesthesia. Overall, the incidence of bradycardia was 
reduced among the norepinephrine group and heart rate was better maintained with 
norepinephrine versus phenylephrine. The use of norepinephrine was accepted as a 
possible alternative vasopressor in the obstetric setting but concluded that further 
research is needed to assess the overall safety of norepinephrine. 




Summary and Conclusions 
 Maternal hypotension is a common occurrence after the administration of spinal 
anesthesia for cesarean delivery and if left untreated can be dangerous for both mother 
and fetus. Maternal side effects of untreated hypotension can range from nausea and 
vomiting, to unconsciousness and eventual cardiac arrest (Nagelhout et al., 2013). 
Maternal hypotension can impact uteroplacental perfusion and potentially impact the 
fetus by impairing maternal-fetal gas exchange (Stewart et al., 2010). The mainstay 
treatment for maternal hypotension is phenylephrine, a direct-acting α1-adrenergic 
agonist. However, stimulation of α1 receptors can cause a reflexive decrease in heart rate 
and consequent decrease in cardiac output which theoretically could have a negative 
impact on fetal wellbeing (Carvalho & Dyer, 2015; Ryu et al., 2019). Norepinephrine, a 
vasopressor more commonly used in intensive care units, has α1-adrenergic agonist with 
mild β1-agonist properties and can maintain blood pressure and heart rate, consequently 
maintaining cardiac output (Nagelhout et al., 2013). The purpose of this paper was to 
conduct a systematic review into the use of norepinephrine versus phenylephrine for the 
treatment of maternal hypotension during spinal anesthesia for cesarean delivery.  
 Using the databases CINAHL, MEDLINE, Google Scholar and PubMed a 
comprehensive literature review was conducted using search terms chosen by this author. 
Many studies were found on the use of the vasopressors ephedrine or phenylephrine, but 
the use of norepinephrine for treatment of maternal hypotension is a relatively new idea. 




 Utilizing inclusion and exclusion criteria, a total of 15 citations were screened 
through the PRISMA checklist and flow diagram. The five included RCTs selected for 
this systematic review were also analyzed using the CASP checklist to gauge the validity 
and results found. Data was collected and organized into data collection tables, and a data 
synthesis table. Outcomes assessed were maternal hypotension, rates of bradycardia, 
effects on cardiac output, incidence of nausea vomiting, neonatal Apgar scores and 
effects on umbilical cord gases. The efficacy of both drugs to maintain maternal blood 
pressure and preserve heart rate was specifically compared. 
  All five studies found no difference between medication study groups in 
rates of hypotensive episodes. Cardiac output was analyzed in two RCTs and resulting 
data was conflicting; Ngan Kee et al., 2015 found normalized CO at 5 minutes was 
greater in the norepinephrine group while Vallejo et al., 2017 found no variation between 
groups. Three out of five studies found that norepinephrine preserved heart rate better 
than phenylephrine. Maternal and neonatal outcomes were similar between study groups. 
Only one study found that rates of vomiting were higher among the phenylephrine group, 
while the other four studies found similar rates of nausea and vomiting between groups. 
Fetal Apgar scores at 1 minute and 5 minutes were also found to be similar between 
groups. Unfortunately, no pattern was found among umbilical cord gases; furthering the 
argument for further study.  
 There were several limitations to this systematic review. Due to the novelty of the 
use of norepinephrine in obstetrics, only five studies met inclusion criteria for this 
systematic review. Among those selected there were variations in drug administration 




Further comprehensive research is indicated. Variations in dosage of medications also 
made direct comparison difficult as well.  Ngan Kee et al., 2015 used a potency ratio of 
20:1 norepinephrine versus phenylephrine, yet Vallejo et al., 2017 used a potency ratio of 
2:1. There was no consensus on true potency ratios between studies and further research 
is warranted. Lastly a potential limitation was that only four databases were searched 
which could have excluded potential research. 
 In summary, this systematic review shows that norepinephrine may be considered 
a possible alternative for phenylephrine for the treatment of maternal hypotension 
following spinal anesthesia during cesarean delivery. However, further research is 
warranted into the safety and effects on umbilical cord gases before routine clinical 
utilization.  
 Next, the recommendations and implications for advanced nursing practice will 
be discussed.  














Recommendations and Implications for Advanced Nursing Practice 
  Certified Registered Nurse Anesthetists (CRNAs) provide anesthesia to women 
undergoing cesarean deliveries every day across the nation. A hallmark of the CRNA’s 
practice is the ability to adapt and advance their field by utilizing evidenced-based 
research. While the occurrence of maternal hypotension is commonly occurring side 
effect of spinal anesthesia, it can be mitigated and lessened with administration of 
vasopressors. Administering the superior vasopressor can improve maternal and fetal 
outcomes. 
 Phenylephrine is the current first line drug of choice for maternal hypotension, yet 
as this systematic review demonstrated, it has a propensity to reduce heart rate. 
Norepinephrine has similar ability to maintain blood pressure without depressing the 
heart rate which could potentially maintain uteroplacental blood flow better then 
phenylephrine. The alterations to cardiac output and subsequently uteroplacental blood 
flow is likely more significant in compromised mothers or fetuses. As previously 
mentioned, literature is scarce on the use of norepinephrine and the field could benefit 
from more well-designed, large randomized control trials that include high risk patients. 
Further study could also demonstrate appropriate potency and ideal method of 
administration.  
 For the Advanced Practice Nurse, such as the CRNA, knowledge of the 
medications administered is paramount for reduction in morbidity and mortality. As 
discussed earlier, one of the concerns regarding norepinephrine is the risk of tissue 




demonstrate the rate of complications to be very low, a limitation to their study was the 
small sample size of 55 patients. Understanding risk mitigation strategies such as 
utilizing a large bore IV placed in the antecubital fossa or through a central line is crucial 
for the APRN. It should be noted that in the five selected studies for this systematic 
review, none reported any complications from the peripherally administered 
vasopressors. Further research is warranted into the rates of complications from 
peripherally administrated norepinephrine and prior to any implementation of routine 
clinical use, a hospital policy would have to be put in place to assure proper 
administration.  
 Historically shifting clinician’s workflow and habits have been met with 
resistance. Despite widespread evidence that phenylephrine was superior to the 
previously first line agent, ephedrine, it took many years for systemic change and for 
phenylephrine to be considered the ‘gold-standard.’ Even with the suggested continued 
research into norepinephrine’s efficacy and safety within obstetrics, any changes to 
practice should be anticipated to be met with hesitancy. Phenylephrine is a very 
commonly used medication within the operating room and CRNAs are comfortable with 
its medication profile while norepinephrine has been typically reserved for intensive care 
and the cardiac anesthesia specialty. A lack of familiarity with norepinephrine could 
increase the challenge to any change in practice (Carvalho & Dyer, 2015).  
The use of norepinephrine over phenylephrine for the treatment of maternal 
hypotension could have potential benefits to patient undergoing cesarean delivery, 
especially patients who are already hemodynamically compromised. Further research 




widespread change to standards of practice. Continuing education on norepinephrine’s 
dosages, side effects and risks should be implemented prior to use. Further research 
should also be completed on the incidence of complications from peripherally 
administered norepinephrine. Through furthering the research on the use of specific 
vasopressors among the obstetric population, reductions to patient morbidity and 
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to maintain maternal 
blood pressure in 
parturients undergoing 
spinal anesthesia  
Setting/Sample: 104 
patients enrolled at 
Prince of Wales 
Hospital, Hong Kong, 
China. Inclusion 
criteria was ASA status 
I-II, singleton, term 
pregnancy, and 
scheduled elective 
cesarean with routine 
spinal anesthesia. 101 
patients included in the 
final study 
Anesthesia 



















Patients were randomized into 
either the norepinephrine group or 
phenylephrine group and received 
infusions of either norepinephrine 
5 mcg/mL (n=49) or 
phenylephrine 100 mcg/mL (n=52) 
administered via a closed loop 
feedback computer system based 
off hemodynamic parameters. 
Maternal blood pressure and heart 
rate were measured in 1-minute 
intervals, CO, SVR and CI were 
measured at 5-minute intervals. 
Apgar scores were assessed 1 
minute and 5 minutes after 
delivery. Umbilical arterial and 
venous blood were collected.  
Outcomes 
HR and CO averaged higher in the 
norepinephrine group versus the 
phenylephrine group. Systolic BP were 
similar between groups. SVR was lower in 
the norepinephrine group but there was no 
difference in SV. Incidence of bradycardia 
(HR <60 beats/min) was higher in the 
phenylephrine group (55.8%, P <0.001) 
versus norepinephrine (18.4%). Three 
patients (6.1%) in the norepinephrine 
group had nausea or vomiting versus two 
patients (3.8%) in the phenylephrine group 
(p=0.67).  
Apgar scores at 1 and 5 minutes were 
similar between groups. UV pH and UV 
oxygen content were higher in the 
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ephedrine in parturient 
women with 
preeclampsia who had 
hypotension following 
spinal anesthesia for 
cesarean delivery.   
Setting/Sample: 315 
patients in Nanjing, 
China. Inclusion was 
ASA I or II, singleton, 
non-laboring, 















patient was in 







infused at a 
maximum rate 
of 10ml/kg.  
Intervention 
Patients were randomized into 
either the norepinephrine group 
(n=56), the phenylephrine group 
(n=55), or the ephedrine group 
(n=55).    
 
Maternal blood pressure and heart 
rate were measured in 1-minute 
intervals from intrathecal 
injection until delivery. Maternal 
complications such as nausea, 
vomiting, dizziness and shivering 
were also recorded.  
Apgar scores were assessed 1 
minute and 5 minutes after 
delivery. Umbilical arterial blood 
gas and pH was analyzed.  
Outcomes 
The standardized HR over time was higher 
in the norepinephrine group then the 
phenylephrine. Norepinephrine had a lower 
incidence of tachycardia (HR >120) then 
ephedrine (16.1 vs. 36.4%, 95% CI,) and a 
lower incidence of bradycardia (HR <60) 
then phenylephrine (3.6% vs. 21.8%, 95% 
CI). Incidence of IONV, dizziness and 
shivering were similar between 
norepinephrine and phenylephrine.  
Apgar and umbilical artery blood gas 
between the norepinephrine and 




blood flow was 
not measured 
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Purpose: Compare 
prophylactic, fixed-rate 
intravenous infusion of 
phenylephrine and 
norepinephrine during 
cesarean delivery under 
spinal anesthesia.  
Setting/Sample: 85 
patients from 8/2014-
8/2015 in West Virginia. 
Inclusion was ASA <3, 
singleton gestation, >36 
weeks, scheduled elective 
CD under spinal anesthesia. 
Exclusion was hypertensive 
disease, preeclampsia, 
eclampsia, use of cardiac 
medication or medication 
for blood pressure control, 
previous gastric bypass, 
history of chronic opioid 
use, BMI >40, emergency 





















Patients were randomized 
into the phenylephrine group 
(n=38), or the 
norepinephrine group 
(n=43). Four patients were 
excluded from the 
norepinephrine group 
because of monitoring 
equipment failure, or 
emergency cesarean 
delivery. The phenylephrine 
group received 100 mcg/mL 
infused at 0.1 mcg/kg/min 
and the norepinephrine 
group received 0.05 
mcg/kg/min to maintain SBP 
within 100-120% of 
baseline. Rescue boluses of 
100mcg of phenylephrine 
were administered if BP fell 
below 100% of baseline. 
Rescue boluses of ephedrine 
were given for bradycardia 
(HR <60). 
Outcomes 
 There were no differences between the 
two groups in infusion duration, 
incidence of bradycardia or incidence 
of nausea, but the incidence of emesis 
was greater in the phenylephrine group 
(Group P=26.3%, Group N=16.3%).  
The proportion of patients who 
received ≥ 1 rescue phenylephrine 
dose was similar between groups 
(Group P=52.6% vs. Groups 
N=46.5%). The proportion of patients 
who received ≥1 bolus of rescue 
ephedrine was greater in the 
phenylephrine group (Group P: 23.7% 
vs. Group N: 2.3%) 
There was no difference between 
groups in the proportion of Apgar 
scores <7 at 1 minute and 5 minutes or 
in umbilical venous cord blood gases.  
No significant differences in HR, Co, 
CI, SV and/or SVR were found.  
Limitations 
High rates of nausea 
and vomiting could 
be attributed to 
intrathecal morphine 
and fentanyl. The 
study was unblinded 
which could have 
led to bias. Another 
limitation is that the 
fixed-rate infusion 
of phenylephrine 
was low (about 
8mcg/min in an 80 
kg woman) which is 
lower than most 
current regimens. 
High incidences of 
nausea and vomiting 
could presumably 
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Purpose: To compare 
norepinephrine and 
phenylephrine efficacy when 
used as intermittent bolus 
regimens to prevent and treat 
spinal-induced hypotension.  
Sample/Setting: 112 women 
were enrolled at Mount Sinai 
Hospital in Toronto, ON, Canada 
from 1/3/2017-4/17/17. 
Inclusion criteria was elective c-
section under spinal anesthesia, 
ASA status ≤III, ≥18 years of 
age, singleton pregnancy, ≥36-
week gestation, body weight 50-







cerebrovascular disease, fetal 
abnormalities, history of diabetes 
and patient refusal.  
 
Anesthesia 











solution to a 
maximum of 1L.   
Intervention 
Patients were randomized 
into the phenylephrine 
group (n=56), or the 
norepinephrine group 
(n=56). Patients were 
bloused with either 
6mcg/mL of norepinephrine 
or 100mcg/mL of 
phenylephrine depending 
on group allocation. 
Hypotension was defined as 
SBP <80% baseline. 
Ephedrine 10mg was rescue 
medication in both groups 
if SBP was below baseline 
and HR was <60 bpm.  
Outcomes 
 Incidence of bradycardia (HR <50 
bpm) were lower in the 
norepinephrine group (10.9% versus 
37.5%). Pts in the phenylephrine 
group were at a higher risk of 
multiple episodes of bradycardia 
versus the norepinephrine group. 
There was no difference in rates of 
hypotension between groups. 
Patients requiring rescue boluses of 
ephedrine were higher in the 
phenylephrine group (21.4% versus 
7.2%) There was no difference 
between the groups in incidence of 
hypertension, tachycardia, nausea, or 
vomiting.  
No difference was found in fetal 
Apgar scores at 1 and 5 minutes or in 
umbilical cord blood gases.   
Limitations 
HR was used as a 
surrogate marker 
of cardiac output 
and was not 
directly 
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Purpose: Compare the 
efficacy, safety, side-
effect profile and 





women were included 
from December 2016-
January 2018 in Delhi, 
India. Inclusion criteria 
was an uncomplicated, 
singleton elective c-
section with spinal 
anesthesia. Exclusion 
criteria was preexisting 
medical conditions, 
placenta previa, fetal 
malformations, systolic 
arterial pressure <100 
mmHg or fetal weight 
extremes. The 
investigators and the 
patients were blinding to 






2mL if patient 
was <150cm in 
height. Patients 
were coloaded 




Patients were randomized into 
either the phenylephrine group 
(n=45) or the norepinephrine 
group (n=45). Hypotension 
was defined as a decrease of 
≥20% from baseline systolic 
blood pressure or a decrease 
below 100 mmHg systolic 
blood pressure. Bradycardia 
was defined as a heart rate of 
less than 60 beats per minute 
with 0.6 mg IV of atropine 
being the rescue medication 
for a heart rate less than 45 
beats per minute.  For 
hypotensive episodes, a series 
of 1-mL bolus of either 100 
mcg/mL of phenylephrine or 5 
mcg/mL of norepinephrine 
were administered until blood 
pressures were corrected.  
Outcomes 
The primary outcome measured was 
incidence of maternal bradycardia after 
medication administration. Incidence of 
bradycardia were higher in the 
phenylephrine group (37.8%) versus the 
norepinephrine group (22.2%). No 
differences were found in the number of 
hypotensive periods; however, the total 
number of boluses were higher in the 
phenylephrine group (median dose 200mcg) 
versus the norepinephrine group (median 
dose 5mcg). The mean heart rate 1 minute 
after study drug administration was lower in 
the phenylephrine group (76.8 beats/min) 
versus the norepinephrine group (88.3 
beats/min). There were no differences in the 
incidence of nausea, vomiting nor dizziness.  
Fetal umbilical blood gases were found to 
be significantly higher in the phenylephrine 
group verses the norepinephrine group. 
There was no significant difference in 
Apgar scores at 1 minute or 5 minutes.  
Limitations 
The study 
used a dose 



























Critical Appraisal Skills Program (CASP) tables 
Table C-1 
Citation: Ngan Kee, W. D., Lee, S. W. Y., Ng, F. F., Tan, P. E., & Khaw, K. S. (2015). 
Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance 
of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology, 122(4), 736-
745. doi: 10.1097/ALN.0000000000000601. 
Question Yes Can’t 
Tell 
No 
Did the trial address a clearly focused issue?  ✔   
Was the assignment of patients to treatments randomized?  ✔   
Were all of the patients who entered the trial properly accounted for at its 
conclusion? 
✔   
Were patients, health workers and study personnel ‘blind’ to treatment?  ✔   
Were the groups similar at the start of the trial?  ✔   
Aside from the experimental intervention, were the groups treated equally?  ✔   
How large was the treatment effect? The primary outcomes assessed were HR 
and CO. A varied number of blood pressure and HR measurements were recorded 
due to the varying time for each measurement. Cardiac output was recorded a 
minimal of four times for each patient.  
✔   
How precise was the estimate of the treatment effect? The authors calculated 
that a sample size of 47 patients per group would have greater than 90% power to 
detect a 20% difference in cardiac output between groups. To allow for study 
dropouts the sample size was increased by 5% with a goal of 52 patients per group. 
✔   
Can the results be applied to the local population, or in your context?   ✔  
Were all clinically important outcomes considered? ✔   







Citation: Wang, X., Mao, M., Liu, S., Xu, S., Yang, J. (2019). A comparative study of bolus 
norepinephrine, phenylephrine, and ephedrine, for the treatment of maternal hypotension in 
parturients with preeclampsia during cesarean delivery under spinal anesthesia. Medicine Science 
Monitor, 25, 1093-1101. doi:10.12659/MSM.914143 
 
Question Yes Can’t 
Tell 
No 
Did the trial address a clearly focused issue?  ✔   
Was the assignment of patients to treatments randomized?  ✔   
Were all of the patients who entered the trial properly accounted for at its 
conclusion? 
✔   
Were patients, health workers and study personnel ‘blind’ to treatment?  ✔   
Were the groups similar at the start of the trial?  ✔   
Aside from the experimental intervention, were the groups treated equally?  ✔   
How large was the treatment effect? The primary outcome was overall maternal SBP 
and HR, secondary outcomes were incidence of tachycardia, bradycardia and 
hypertension.  
✔   
How precise was the estimate of the treatment effect? Using a pilot study as 
reference, a minimum of 49 cases per group was needed to detect statistically 
significant differences in maternal tachycardia. The sample size for this study was 
increased to 55 in each group to account for drop out. 
✔   
Can the results be applied to the local population, or in your context?  ✔   
Were all clinically important outcomes considered? ✔   
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Hobbs, G. R., … Ranganathan, P. (2017). An open-label randomized controlled clinical trial for 
comparison of continuous phenylephrine versus norepinephrine infusion in prevention of spinal 
hypotension during cesarean delivery. International Journal of Obstetric Anesthesia, 29, 18-25. 
doi:10.1016/j.ijoa.2016.08.005 
Question Yes Can’t 
Tell 
No 
Did the trial address a clearly focused issue?  ✔   
Was the assignment of patients to treatments randomized?  ✔   
Were all of the patients who entered the trial properly accounted for at its 
conclusion? 
✔   
Were patients, health workers and study personnel ‘blind’ to treatment? 
Anesthesia providers were made aware of the study drug selected upon patient entering 
the operating room. 
  ✔ 
Were the groups similar at the start of the trial?  ✔   
Aside from the experimental intervention, were the groups treated equally?  ✔   
How large was the treatment effect? The primary endpoint was the number and total 
dose of rescue bolus interventions needed to maintain SBP. Incidence of N/V, 
bradycardia, Apgar scores were also compared using the chi-square test. 
✔   
How precise was the estimate of the treatment effect? A local pilot study was 
assessed and based off power analysis 35 patients were required per group to detect a 
reduction to 10% of the incidence of hypotension at the 0.05 significance level with 
80% power.  
✔   
Can the results be applied to the local population, or in your context?   ✔  
Were all clinically important outcomes considered? ✔   







 Table C-4 
Citation: Sharkey, A. M., Siddiqui, N., Downey, K., Ye, X. Y., Guevara, J., Carvalho, J. C. A.. 
(2018). Comparison of intermittent intravenous boluses of phenylephrine and norepinephrine to 
prevent and treat spinal-induced hypotension in cesarean deliveries: randomized controlled trial. 
Anesthesia & Analgesia, 129(5), 1312-1318. doi:10.1213/ANE.0000000000003704 
Question Yes Can’t 
Tell 
No 
Did the trial address a clearly focused issue?  ✔   
Was the assignment of patients to treatments randomized?  ✔   
Were all of the patients who entered the trial properly accounted for at its 
conclusion? 
✔   
Were patients, health workers and study personnel ‘blind’ to treatment?  ✔   
Were the groups similar at the start of the trial?  ✔   
Aside from the experimental intervention, were the groups treated equally?  ✔   
How large was the treatment effect? The primary outcome was the incidence of any 
maternal bradycardia. Secondary outcomes included the incidence of hypotension, 
hypertension, tachycardia, N/V and umbilical gases and Apgar scores. 
✔   
How precise was the estimate of the treatment effect? Sample size was based of 2 
previous studies done by the authors group. A sample size of 56 patients per group 
would have an 80% power to detect a 70% relative decrease in incidence of 
bradycardia.  
✔   
Can the results be applied to the local population, or in your context?  ✔   
Were all clinically important outcomes considered? ✔   
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controlled trail of phenylephrine and noradrenaline boluses for treatment of postspinal 
hypotension during elective caesarean section. Association of Anaesthestists, 74, 850-855. 
doi:10.111/anae.14675 
Question Yes Can’t 
Tell 
No 
Did the trial address a clearly focused issue?  ✔   
Was the assignment of patients to treatments randomized?  ✔   
Were all of the patients who entered the trial properly accounted for at its 
conclusion? 
✔   
Were patients, health workers and study personnel ‘blind’ to treatment?  ✔   
Were the groups similar at the start of the trial?  ✔   
Aside from the experimental intervention, were the groups treated equally?  ✔   
How large was the treatment effect? The primary goal was to assess the incidence of 
maternal bradycardia after study drug administration. Secondary outcomes were blood 
pressure, vasopressor requirements, maternal complications, and neonatal outcomes. 
✔   
How precise was the estimate of the treatment effect? Utilizing information from a 
previously done study, a sample size of 45 patients was required using one-sided, 
two=proportion z-test method with pooled variance, with a power of 80% at a 5% 
significance level.  
✔   
Can the results be applied to the local population, or in your context?  ✔   
Were all clinically important outcomes considered? ✔   


























Apgar Scores  
Umbilical Cord 
Gases 
Ngan Kee et 
al., 2015 








(Defined as SBP <80% 
baseline) SBP was 
maintained similarly 
between groups (P=0.36) 
Normalized CO at 5 
minutes was greater 
in the N group 
(median 102.7% 
[94.3-116.7%] 
versus P group 
(93.8% [85.0-
103.1%]) (p=0.004) 
(Defined as HR <60 
bpm). Lower in the 
N group (18.4%) 
versus P group 
(55.8%, p<0.001) 
No statistical 
difference was found 
between groups in 
rates of N/V (Group 
N n=3, 6.1%; Group P 
n=2, 3.8%; P=0.67). 
Apgar scores for 
both groups 
were greater 
than 7 at 1 





UA pH was similar 
between groups; N 
group (7.30 [7.28-
7.33]) and P group 
(7.29 [7.28-7.32]) 
P=0.45). UA PCO2 
was similar between 
groups; group P (52 
[48-56]), Group P 
(50 [48-56]) 
(P=0.77) 
UV pH was greater 
in group N  (7.35 
[7.34-7.37]) vs P 
group (7.34 [7.32-
7.36]) (P=0.031) 
UV oxygen content 
was higher in group 
N (12.7 [11.3-14.4]) 
vs group P (11.8 
[9.6-13.7]) 
(P=0.047) 












(Defined as SBP <80% 
of baseline) No statistical 
difference was found in 
overall SBP over time 
between groups (Group 
N 125.1 ±8.5, group P 
124.2±6.6, group E 
123.1±6.8).  
The number of 
hypotensive episodes 
 (Defined as HR <60 
bpm) Lower in 
group N (3.6%) 
versus group P 
(21.8%) (P=0.004) 
Rates of nausea in 
group N were (3.5%), 
group P (5.5%), and 
group E (9.1%). Rates 
of vomiting in group 
N were (1.8%), group 
P (1.8%) and group E 
(11%). Overall 
combined N/V rates 





Apgar score was 
<9 at 5 minutes 
No differences were 
found in UA blood 
gases from group N 
and group P. UA pH 
was higher in group 
N (7.32 ±0.02) vs 
group E (7.31±0.03) 
(P=0.006). UA 
lactate was lower in 




with 24 hour 
proteinuria ≥300 





group N (5.4%) 
versus group P (7.3%) 
and group E (20%) 
(P=0.02).  
vs group E (1.8±0.5) 
(P=<0.001) 







(Defined as an SBP 
decrease <100% of 
baseline) Incidence of 
hypotension were treated 
with recue boluses of 
phenylephrine and/or 
ephedrine (given for 
hypotension with 
bradycardia). The groups 
were similar in who 
received ≥1 vasopressor 
bolus (Group P 65.8% 
[n=25] vs Group N: 
46.5% [n=21], P=0.12). 
The incidence one or 
more phenylephrine 
rescue boluses were 
similar (Group P: 52.6% 
[n=20] vs. group N: 
46.5% [n=20], P=0.58). 
The incidence of ≥1 
ephedrine bolus was 
greater in group P 
(23.7%, [n=9]) vs group 




found in CO 
between groups 
(P=0.5) 
(Defined as a HR 




groups (group P: 
23.7% vs group N: 
18.6%, P=0.58) 
All patients received 
prophylactic 
ondansetron 4mg after 
delivery of the baby.   
Incidence of nausea 
was similar between 
groups (Group P 
63.2% vs group N 
51.2%, P=0.28). The 
incidence of emesis 
was greater in group P 
(26.3%) vs group N 
(16.3%) (P<0.001) 
Apgar scores <7 
at 1 minute were 
similar between 
groups (Group 
P=6 vs group 
N=6, P=0.82). 
Apgar scores <7 
at 5 minutes 
were also 
similar (Group 
P=2 vs group 
N=1, P=0.48) 
UV were only 
obtained if clinically 
indicated.  
UV pH were similar 
between groups 
(Group N 7.30 
[n=5] vs group N 
7.27 [n=7], P=0.42) 
Sharkey et 
al., 2018 
ASA ≤III, ≥18 








(Defined as an SBP 
<80% of baseline value) 
Rates of hypotension 
were similar between the 
two groups (group N 
38% vs group P 39%, 
P=0.9). The incidence of 
patients requiring rescue 
boluses of ephedrine for 
2 consecutive SBP <80% 
of baseline with or 
without a HR <60bpm 
were lower in group N 
(7.2%) vs group P 
(21.4%)  
 (Defined as an HR 
<50 bpm) Rates of 
bradycardia were 
lower in group N 
(10.9%) versus 
group P (37.5%) 
(P=<0.001)  
Incidences of nausea 
and vomiting were 
similar between 
groups. Group P 
(32.1% and 7.1%) vs 
group N (27.3% and 
1.8%) (P=0.57 and 
P=0.17) respectively. 
Apgar scores at 
1 and 5 minutes 





No difference was 
seen in umbilical 





















(Defined as a decrease of 
≥20% from baseline SBP 
or an absolute value 
<100 mmHg). No 
statistical difference was 
found between the 
groups in number of 
hypotensive episodes, or 
the number of boluses to 
treat the first episode of 
hypotension. 
Hypotensive episodes 
group P (n=2) vs group 
N (n=1), (P=0.06). The 
total number of 
vasopressor boluses 
required to treat 
hypotensive episodes 
was higher in group P 
than group N (P=0.01). 
 (Defined as a HR of 
<60 bpm) The 
incidence of 
bradycardia in group 
P was 37.8% verses 
group N 22.2% 
(P=0.17). Rescue 
doses of atropine 
were required in 
group P 6.6% (n=3) 
and group N 2.2% 
(n=1) (P=0.10). 




higher in group N 
(88.3 bpm) vs group 
P (76.8 bpm).  
No statistical 
significance between 
groups in rates of 
nausea or vomiting. 
(P=1.0) 
Apgar scores at 
1 and 5 minutes 







base excess were 
higher in group P vs 
group N.  UA pH 
group P (mean: 
7.29) vs group N 
(7.25), (P=0.03). 
UA pCO2 group P 
(52.2) vs group N 
(53.7). (P=0.52). 
Rates of neonatal 
acidosis (UA pH 
<7.2) in group P 
(15.6%, n=7) vs 
group N (13.3%, 
n=6) (P=0.77) 
